SRRK

Scholar Rock Holding Corp

PDUFA AI-extracted

apitegromab

Spinal Muscular Atrophy

Resolved

102days ago

FDA decision · Mar 27, 2026

What's at stake The FDA's approval decision on apitegromab for Spinal Muscular Atrophy is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.

Primary source · SEC 8-K verified 15h ago

“BLA resubmission and U.S. launch, following FDA approval, are anticipated in 2026”

Add to calendar Post on X Reddit

Provenance